Cytek Biosciences (CTKB) Net Income towards Common Stockholders (2020 - 2026)
Cytek Biosciences posted quarterly Net Income towards Common Stockholders of -$18.9 million for Q1 2026, down 65.46% year-on-year from -$54.6 million in Q1 2025, and up 57.2% on a QoQ basis from -$44.1 million in Q4 2025.
Cytek Biosciences (CTKB) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$18.9 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 65.46% year-over-year to -$18.9 million; the trailing twelve-month figure through Mar 2026 stood at -$74.0 million (down 557.69% YoY), and the FY2025 full-year result was -$66.5 million, down 1005.3% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$18.9 million, up from -$44.1 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $9.6 million in Q4 2024 and bottomed at -$44.1 million in Q4 2025.
- The 5-year median for Net Income towards Common Stockholders is -$5.5 million (2025), against an average of -$5.9 million.
- Peak annual rise in Net Income towards Common Stockholders reached 381.5% in 2022, while the deepest fall reached 2081.37% in 2022.
- A 5-year view of Net Income towards Common Stockholders shows it stood at $3.5 million in 2022, then soared by 55.94% to $5.5 million in 2023, then surged by 75.23% to $9.6 million in 2024, then sank by 557.08% to -$44.1 million in 2025, then soared by 57.2% to -$18.9 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$18.9 million (Q1 2026), -$44.1 million (Q4 2025), and -$5.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 199.50 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Cytek Biosciences | - | - | 21.25 Mn | -18.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.87 Mn |
| Dec 31, 2025 | -44.08 Mn |
| Sep 30, 2025 | -5.48 Mn |
| Jun 30, 2025 | -5.58 Mn |
| Mar 31, 2025 | -11.40 Mn |
| Dec 31, 2024 | 9.64 Mn |
| Sep 30, 2024 | 941,000.00 |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -6.17 Mn |
| Dec 31, 2023 | 5.50 Mn |
| Sep 30, 2023 | -6.46 Mn |
| Jun 30, 2023 | -4.39 Mn |
| Mar 31, 2023 | -6.81 Mn |
| Dec 31, 2022 | 3.53 Mn |
| Sep 30, 2022 | 1.67 Mn |
| Jun 30, 2022 | -598,000.00 |
| Mar 31, 2022 | -2.02 Mn |
| Sep 30, 2021 | 346,000.00 |
| Mar 31, 2021 | 102,000.00 |
| Dec 31, 2020 | 575,000.00 |
| Sep 30, 2020 | 1.45 Mn |
| Jun 30, 2020 | 1.90 Mn |